[go: up one dir, main page]

NO20091644L - Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist - Google Patents

Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist

Info

Publication number
NO20091644L
NO20091644L NO20091644A NO20091644A NO20091644L NO 20091644 L NO20091644 L NO 20091644L NO 20091644 A NO20091644 A NO 20091644A NO 20091644 A NO20091644 A NO 20091644A NO 20091644 L NO20091644 L NO 20091644L
Authority
NO
Norway
Prior art keywords
receptor antagonist
thrombin receptor
oral formulations
lyophilized
rapidly disintegrating
Prior art date
Application number
NO20091644A
Other languages
English (en)
Norwegian (no)
Inventor
Enrico P Veltri
Anastasia Pavlovsky
David Monteith
Suliman Chawdry
Srinivas Duggirala
Michael Angelo Falvo
Ii John R Erbey
Kung-I Feng
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20091644L publication Critical patent/NO20091644L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2063Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20091644A 2006-09-26 2009-04-24 Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist NO20091644L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84730606P 2006-09-26 2006-09-26
PCT/US2007/020569 WO2008039406A2 (fr) 2006-09-26 2007-09-24 Formulations lyophilisées à délitement rapide d'un antagoniste du récepteur de la thrombine

Publications (1)

Publication Number Publication Date
NO20091644L true NO20091644L (no) 2009-04-24

Family

ID=39230776

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091644A NO20091644L (no) 2006-09-26 2009-04-24 Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist

Country Status (16)

Country Link
US (1) US20080152712A1 (fr)
EP (1) EP2068823A2 (fr)
JP (1) JP2010504911A (fr)
KR (1) KR20090057400A (fr)
CN (1) CN101541302A (fr)
AR (1) AR062979A1 (fr)
AU (1) AU2007300517A1 (fr)
CA (1) CA2664290A1 (fr)
CL (1) CL2007002759A1 (fr)
CO (1) CO6170417A2 (fr)
MX (1) MX2009003360A (fr)
NO (1) NO20091644L (fr)
PE (1) PE20080673A1 (fr)
TW (1) TWI343262B (fr)
WO (1) WO2008039406A2 (fr)
ZA (1) ZA200902592B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
US20080194560A1 (en) * 2006-12-22 2008-08-14 Zhi Yun Wang Disintegration promoters in solid dose wet granulation formulations
EP2358366A1 (fr) * 2008-11-17 2011-08-24 Schering Corporation Schémas posologiques d'un antagoniste du récepteur de la thrombine basés sur la pharmacocinétique
DK2438060T3 (da) 2009-06-04 2014-01-13 Merck Sharp & Dohme Aktiv metabolit af en trombin-receptor-antagonist
EP2440191A2 (fr) 2009-06-08 2012-04-18 Schering Corporation Antagoniste du récepteur de la thrombine et comprimé de clopidogrel à dose fixe
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
CN102933207B (zh) 2009-10-30 2018-02-02 Ix生物医药有限公司 快速溶解固体剂型
TR201601548A2 (tr) 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (fr) 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. Nouvelle composition pharmaceutique à base de vorapaxar et de métoprolol

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
JPH07116022B2 (ja) * 1989-04-18 1995-12-13 三共株式会社 凍結乾燥製剤の製法
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1246668B1 (fr) * 1999-12-01 2005-11-30 Natco Pharma Limited Composition pharmaceutique lyophilisee a action rapide s'administrant par voie orale utilisee pour traiter la migraine
AU6323001A (en) * 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
AU2001266900B2 (en) * 2000-06-15 2007-04-05 Merck Sharp & Dohme Corp. Thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US6740657B2 (en) * 2001-02-23 2004-05-25 Ortho-Mcneil Pharmaceutical, Inc. Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
CA2449118A1 (fr) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Pyrimidine inhibitrice de la cdk, sa production et son utilisation comme medicament
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
CA2463628A1 (fr) * 2001-10-18 2003-04-24 Schering Corporation Analogues d'himbacine tels que des antagonistes recepteurs de lathrombine
ATE378330T1 (de) * 2002-04-16 2007-11-15 Schering Corp Trizyklische thrombin rezeptor antagonisten
US20070202140A1 (en) * 2005-12-22 2007-08-30 Veltri Enrico P Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist

Also Published As

Publication number Publication date
AU2007300517A1 (en) 2008-04-03
CA2664290A1 (fr) 2008-04-03
AR062979A1 (es) 2008-12-17
PE20080673A1 (es) 2008-06-14
KR20090057400A (ko) 2009-06-05
CL2007002759A1 (es) 2008-03-24
WO2008039406A3 (fr) 2008-07-03
JP2010504911A (ja) 2010-02-18
CO6170417A2 (es) 2010-06-18
WO2008039406A2 (fr) 2008-04-03
TW200820995A (en) 2008-05-16
US20080152712A1 (en) 2008-06-26
TWI343262B (en) 2011-06-11
MX2009003360A (es) 2009-04-14
CN101541302A (zh) 2009-09-23
EP2068823A2 (fr) 2009-06-17
ZA200902592B (en) 2010-03-31

Similar Documents

Publication Publication Date Title
NO20091644L (no) Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist
NO20081844L (no) Terapeutiske forbindelser
NO20092476L (no) Antibakterielle polycykliske ureaforbindelser
NO20074703L (no) Antibakterielle piperidinderivater
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
WO2008027557A3 (fr) Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
NO20081593L (no) Depotsammensetning
FI2498756T4 (fi) Neratinibimaleaatin tablettiformulaatiot
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
WO2005105088A3 (fr) Procedes d'utilisation et compositions comportant des composes immunomodulateurs pour le traitement et le controle de l'hypertension pulmonaire
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
MX2010003923A (es) Formulacion farmaceutica de valsartan.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
ECSP088240A (es) Composición de trazodona para administración una vez por día
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
WO2008142572A3 (fr) Formulation de comprimé à libération contrôlée contenant de l'aluminométasilicate de magnésium
ES2282062T1 (es) Composicion farmaceutica que contiene irbesartan.
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
CY1109405T1 (el) Στοματο-διασπειρομενα δισκια δομπεριδονης

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application